According to a recent LinkedIn post from MintNeuro, the U.K.’s Advanced Research + Invention Agency (ARIA) has opened a £50 million funding call for its Massive Scalable Neurotechnologies program. The initiative targets technologies that can access and modulate the central nervous system through the body’s natural pathways, with a goal of minimally invasive, rapidly deployable neural interfaces.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post highlights that ARIA’s objectives align with MintNeuro’s focus on making neurotechnology smaller and less invasive, emphasizing integrated circuits as a key enabler for scalable devices. MintNeuro indicates interest in collaborating with applicants on silicon, packaging, integration, and evaluation hardware, positioning the company as a potential enabling partner rather than a direct grant recipient.
From an investor perspective, this funding call could expand the addressable market for neurotechnology hardware providers like MintNeuro if the program catalyzes new device platforms and clinical use cases. The company’s positioning around core enabling technologies suggests potential for design wins, strategic partnerships, or future revenue from supplying components to ARIA-backed projects.
The post also suggests a timeline for near-term activity in the ecosystem, with applications opening on February 24, 2026 and a concept paper deadline of March 17, 2026. This schedule may drive a wave of collaborations and project consortia formation in early 2026, in which MintNeuro could secure early role visibility and deepen its relationships with both research teams and prospective commercial partners.